

## NOTICE TO THE BAR

### MULTICOUNTY LITIGATION APPLICATION -- NEW JERSEY STATE COURT LITIGATION ALLEGING USE OF OZEMPIC/WEGOVY PRODUCTS CAUSING NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEUROPATHY (NAION)

The Supreme Court has received an application pursuant to Directive #02-19, "Multicounty Litigation Guidelines and Criteria for Designation (Revised)," for Multicounty Litigation (MCL) designation of New Jersey state-court litigation against Novo Nordisk, alleging permanent vision loss (Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)) as a result of use of Ozempic/Wegovy Products.


The MCL application was submitted by counsel for plaintiffs.

Anyone wishing to comment on or object to this application should provide such comments or objections in writing, with relevant supporting documentation, by **August 29, 2025** to:

Hon. Michael J. Blee, J.A.D.  
Acting Administrative Director of the Courts  
Attention: MCL Application – Ozempic/Wegovy  
Hughes Justice Complex, P.O. Box 037  
Trenton, New Jersey 08625-0037

Comments/objections may also be submitted by email to  
[Comments.mailbox@njcourts.gov](mailto:Comments.mailbox@njcourts.gov).

A copy of the application submitted to the Court is posted with this Notice on the Judiciary's Internet Website at ([www.njcourts.gov](http://www.njcourts.gov)) in the Multicounty Litigation Information Center <https://www.njcourts.gov/attorneys/multicounty-litigation>.

A handwritten signature in blue ink that reads "Michael J. Blee" followed by a stylized flourish.

Hon. Michael J. Blee, J.A.D.  
Acting Administrative Director

Dated: July 25, 2025